Coronary/Structural Heart

Arterys Named to the 2019 CB Insights AI 100 List

SAN FRANCISCO, Feb. 6, 2019 /PRNewswire/ — Arterys, the leader in intelligent, cloud-based medical image analysis software, today announced that it has been named for the second consecutive year to CB Insights’ coveted AI 100 ranking, which showcases the 100 most promising private artificial intelligence (AI) companies in the world. Arterys was recognized for its […]

Kaneka invests in a US-based medical device company

TOKYO, Feb. 4, 2019 /PRNewswire/ — Kaneka Corporation (Tokyo, Japan, President: Mamoru Kadokura) has entered into an investment and strategic agreement with an undisclosed US-based medical device company (“Company”). According to this agreement, Kaneka has made an investment in 18.5% shares of the Company and plans to start sales as the exclusive distributor […]

American College of Cardiology Acquires MedAxiom

WASHINGTON, Feb. 4, 2019 /PRNewswire/ — The American College of Cardiology Foundation has acquired MedAxiom, a cardiovascular membership, services and consulting firm, adding the company’s recognized leadership in cardiovascular operations, performance improvement, and business acumen to ACC’s world class science, education, registry, quality improvement and advocacy work. Through this acquisition, the ACC will expand […]

CHMP Recommends Approval of Praluent® (alirocumab) Injection to Reduce Cardiovascular Risk in People with Established Atherosclerotic Cardiovascular Disease

TARRYTOWN, N.Y. and PARIS, Feb. 4, 2019 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Praluent® (alirocumab) Injection, recommending a new indication to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL-C) levels as an […]

Ascyrus Medical Announces CE Mark Approval for the Ascyrus Medical Dissection Stent (AMDS)

BOCA RATON, FLA. (PRWEB) FEBRUARY 01, 2019 With approval, the AMDS offers physicians and patients in Europe the first marketed arch remodeling device and a breakthrough treatment for type A aortic dissections. Ascyrus Medical, a privately-owned medical device company focused on innovative treatments for aortic dissections, today announced the CE mark […]

Altavant Sciences to Present Data Supporting Planned Phase 2 Clinical Program for Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension at PVRI World Congress

BASEL, Switzerland and DURHAM, N.C., Jan. 31, 2019 /PRNewswire/ — Altavant Sciences, a company in the Roivant family focused on clinical development of novel therapies for pulmonary arterial hypertension (PAH) and other indications, will present its latest nonclinical and clinical data at the Pulmonary Vascular Research Institute (PVRI) 13th Annual World Congress on Pulmonary Vascular Disease, […]

Neovasc Announces Renewal of German NUB Status 1 Designation for Neovasc Reducer™ Procedure for Treatment of Refractory Angina

VANCOUVER, Jan. 30, 2019 /PRNewswire/ – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the “Institut für das Entgeltsystem im Krankenhaus” (“InEk”), the […]

Cardiovascular Disease Deaths May Double In U.S. By 2040 If New Treatment Innovations Are Not Discovered, Utilized

BEVERLY HILLS, Calif., Jan. 29, 2019 /PRNewswire/ — Without new treatment options and greater utilization of current cholesterol lowering therapies, the mortality rate from cardiovascular disease (CVD) could increase 62 percent by 2040, according to a study published in the January issue of Clinical Cardiology. While deaths due to CVD have declined over the past 50 years due to improved management […]

Medicure Announces Agreement to Market ReDS™ Device for Congestive Heart Failure Patients in the United States

WINNIPEG, Jan. 28, 2019 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company“) (TSXV:MPH,OTC: MCUJF), a cardiovascular pharmaceutical company, is pleased to announce it has entered into an agreement with Sensible Medical Innovations Inc. (“Sensible”) to become the exclusive marketing partner for the ReDS™ point of care system (“ReDS”) in the United States. ReDS is […]